Burning Rock Biotech Limited American Depositary Shares (BNR)

Price$21.56

Favorite Metrics

Price vs S&P 500 (26W)138.50%

Price vs S&P 500 (4W)-1.39%

Market Capitalization$32.58M

All Metrics

Book Value / Share (Quarterly)$0.73

P/TBV (Annual)2.83x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-1.42%

Cash Flow / Share (Quarterly)$-0.04

Price vs S&P 500 (YTD)-1.56%

Gross Margin (TTM)74.67%

Net Profit Margin (TTM)-10.26%

EPS (TTM)$-0.08

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-0.08

Revenue Growth (5Y)4.65%

EPS (Annual)$-0.08

ROI (Annual)-10.30%

Gross Margin (Annual)74.67%

Net Profit Margin (5Y Avg)-105.68%

Cash / Share (Quarterly)$0.65

Revenue Growth QoQ (YoY)0.23%

ROA (Last FY)-6.75%

Revenue Growth TTM (YoY)4.60%

EBITD / Share (TTM)$-0.08

ROE (5Y Avg)-56.42%

Operating Margin (TTM)-10.16%

Cash Flow / Share (Annual)$-0.14

P/B Ratio2.83x

P/B Ratio (Quarterly)2.83x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)1.93x

Net Interest Coverage (TTM)-10.37x

ROA (TTM)-6.68%

EPS Incl Extra (Annual)$-0.08

Current Ratio (Annual)2.99x

Quick Ratio (Quarterly)2.68x

3-Month Avg Trading Volume0.03M

52-Week Price Return612.76%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.73

P/S Ratio (Annual)2.81x

Asset Turnover (Annual)0.66x

52-Week High$41.72

Operating Margin (5Y Avg)-107.01%

EPS Excl Extra (Annual)$-0.08

CapEx CAGR (5Y)-33.43%

Tangible BV CAGR (5Y)-26.04%

26-Week Price Return147.25%

Quick Ratio (Annual)2.68x

13-Week Price Return-27.52%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.99x

Enterprise Value$152.362

Revenue / Share Growth (5Y)-39.68%

Asset Turnover (TTM)0.65x

Book Value / Share Growth (5Y)-26.45%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)2.29x

Pretax Margin (Annual)-9.97%

Cash / Share (Annual)$0.65

3-Month Return Std Dev140.91%

Gross Margin (5Y Avg)70.34%

Net Income / Employee (TTM)$-0

ROE (Last FY)-10.34%

Net Interest Coverage (Annual)-9.73x

EPS Basic Excl Extra (Annual)$-0.08

P/FCF (TTM)38.48x

Receivables Turnover (TTM)3.10x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.08

Receivables Turnover (Annual)3.10x

ROI (TTM)-9.94%

P/S Ratio (TTM)2.81x

Pretax Margin (5Y Avg)-105.20%

Revenue / Share (Annual)$0.73

Tangible BV / Share (Annual)$0.73

Price vs S&P 500 (52W)577.66%

Year-to-Date Return2.58%

5-Day Price Return15.28%

EPS Normalized (Annual)$-0.08

ROA (5Y Avg)-40.98%

Net Profit Margin (Annual)-10.26%

Month-to-Date Return28.15%

EBITD / Share (Annual)$-0.07

Operating Margin (Annual)-10.16%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-56.40%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.08

P/TBV (Quarterly)2.83x

P/B Ratio (Annual)2.83x

Inventory Turnover (TTM)2.29x

Pretax Margin (TTM)-9.97%

Book Value / Share (Annual)$0.73

Price vs S&P 500 (13W)-30.39%

Beta1.76x

Revenue / Share (TTM)$0.75

ROE (TTM)-9.97%

52-Week Low$2.18

About

Burning Rock Biotech develops NGS-based cancer diagnostics platforms that help oncologists select optimal therapies for patients. The company operates through two revenue-generating channels: a central laboratory model serving smaller hospitals and an in-hospital model for larger medical centers, with the central laboratory business generating the majority of revenues. Its product portfolio includes Pan-HEME, OncoScreen-WES, brPROPHET, and OncoScreen Plus, supplemented by pharma research and development services.